© 1989 British Society for Rheumatology
brief-report |
SYNOVIAL AND SERUM LEVELS OF METHOTREXATE DURING METHOTREXATE THERAPY OF RHEUMATOID ARTHRITIS


*Department of Rheumatology, Ichilov Hospital, Tel Aviv Medical Center, and the Tel Aviv University Sackler Faculty of Medicine Tel Aviv, Israel
Department of Chemical Pathology, Ichilov Hospital, Tel Aviv Medical Center, and the Tel Aviv University Sackler Faculty of Medicine Tel Aviv, Israel
Correspondence to:
1Correspondence to Dr. Moshe Tishler, Department of Rheumatology, Ichilov Hospital, 6 Weismann Street, Tel Aviv, Israel 64239.
Methotrexate (MTX) levels were studied following intravenous MTX in both serum and synovial fluid (SF) of rheumatoid arthritis patients. Two hours after injection serum MTX levels were higher than those of SF. At 24 hours SF levels of MTX exceeded those of the serum, while at 72 hours both blood and SF concentrations were undetectable. The localization of parenteral MTX in the SF may have importance in the understanding of its mechanism and site of action in rheumatoid arthritis.
KEY WORDS: Synovial fluid, Cytotoxic, Pharmacokinetics, Intravenous methotrexate